Inverse agonism of SQ 29,548 and ramatroban on thromboxane A2 receptor

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Chakraborty, Raja ^a,b   Bhullar, Rajinder P ^a   Dakshinamurti, Shyamala ^a,b   Hwa, John ^c   Chelikani, Prashen ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b Biology of Breathing Group Manitoba Institute of Child Health   (Canada)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6,8 DIFLUORO 1,2,3,4 TETRAHYDRO 9 (4 METHYLSULFONYLBENZYL)CARBAZOLE 1 ACETIC ACID; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; CALCIUM ION; DICLOFENAC; RAMATROBAN; THROMBOXANE A2 RECEPTOR;

ARTICLE; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; GENETIC VARIABILITY; HEART PROTECTION; HUMAN; HUMAN CELL; INVERSE AGONISM; MEGAKARYOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION;

AMINO ACID SUBSTITUTION; BLOOD PLATELETS; CALCIUM SIGNALING; CARBAZOLES; DRUG EVALUATION, PRECLINICAL; HEK293 CELLS; HUMANS; HYDRAZINES; INOSITOL 1,4,5-TRISPHOSPHATE; MUTAGENESIS, SITE-DIRECTED; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; SULFONAMIDES;

EID: 84899885201     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085937     Document Type: Article

References (35)

1. Davi G, Santilli F, Vazzana N (2012) Thromboxane receptors antagonists and/or synthase inhibitors. Handb Exp Pharmacol: 261-286.
2. Miggin SM, Kinsella BT (2001) Thromboxane A(2) receptor mediated activation of the mitogen activated protein kinase cascades in human uterine smooth muscle cells. Biochim Biophys Acta 1539: 147-162. (Pubitemid 32522877)
3. Smyth EM, Grosser T, Wang M, Yu Y, FitzGerald GA (2009) Prostanoids in health and disease. J Lipid Res 50 Suppl: S423-428.
4. Gleim S, Kasza Z, Martin K, Hwa J (2009) Prostacyclin receptor/thromboxane receptor interactions and cellular responses in human atherothrombotic disease. Curr Atheroscler Rep 11: 227-235.
5. Hirata T, Kakizuka A, Ushikubi F, Fuse I, Okuma M, et al. (1994) Arg60 to Leu mutation of the human thromboxane A2 receptor in a dominantly inherited bleeding disorder. J Clin Invest 94: 1662-1667.
6. Li Q, Ye K, Blad CC, den Dulk H, Brouwer J, et al. (2007) ZM241385, DPCPX, MRS1706 are inverse agonists with different relative intrinsic efficacies on constitutively active mutants of the human adenosine A2B receptor. J Pharmacol Exp Ther 320: 637-645. (Pubitemid 46147943)
7. Milligan G (2003) Constitutive activity and inverse agonists of G protein-coupled receptors: a current perspective. Mol Pharmacol 64: 1271-1276.
8. Costa T, Ogino Y, Munson PJ, Onaran HO, Rodbard D (1992) Drug efficacy at guanine nucleotide-binding regulatory protein-linked receptors: thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand. Mol Pharmacol 41: 549-560.
9. Milligan G, Bond RA (1997) Inverse agonism and the regulation of receptor number. Trends Pharmacol Sci 18: 468-474.
10. Labrecque P, Roy SJ, Frechette L, Iorio-Morin C, Gallant MA, et al. (2013) Inverse agonist and pharmacochaperone properties of MK-0524 on the prostanoid DP1 receptor. PLoS One 8: e65767.
11. Bylund DB, Toews ML (2013) Quantitative versus qualitative data: The numerical dimensions of drug action. Biochem Pharmacol In press.
12. Wieland K, Bongers G, Yamamoto Y, Hashimoto T, Yamatodani A, et al. (2001) Constitutive activity of histamine h(3) receptors stably expressed in SK-N-MC cells: display of agonism and inverse agonism by H(3) antagonists. J Pharmacol Exp Ther 299: 908-914. (Pubitemid 33104958)
13. Cai G, Gurdal H, Smith C, Wang HY, Friedman E (1999) Inverse agonist properties of dopaminergic antagonists at the D(1A) dopamine receptor: uncoupling of the D(1A) dopamine receptor from G(s) protein. Mol Pharmacol 56: 989-996.
14. Unal H, Karnik SS (2012) Domain coupling in GPCRs: the engine for induced conformational changes. Trends Pharmacol Sci 33: 79-88.
15. Chakraborty R, Pydi SP, Gleim S, Dakshinamurti S, Hwa J, et al. (2012) Site-Directed Mutations and the Polymorphic Variant Ala160Thr in the Human Thromboxane Receptor Uncover a Structural Role for Transmembrane Helix 4. PLoS One 7: e29996.
16. Gleim S, Stitham J, Tang WH, Li H, Douville K, et al. (2013) Human thromboxane A2 receptor genetic variants: in silico, in vitro and "in platelet" analysis. PLoS One 8: e67314.
17. Fontana P, Alberts P, Sakariassen KS, Bounameaux H, Meyer JP, et al. (2011) The dual thromboxane receptor antagonist and thromboxane synthase inhibitor EV-077 is a more potent inhibitor of platelet function than aspirin. J Thromb Haemost 9: 2109-2111.
18. Lesault PF, Boyer L, Pelle G, Covali-Noroc A, Rideau D, et al. (2011) Daily administration of the TP receptor antagonist terutroban improved endothelial function in high-cardiovascular-risk patients with atherosclerosis. Br J Clin Pharmacol 71: 844-851.
19. Ogletree ML, Harris DN, Greenberg R, Haslanger MF, Nakane M (1985) Pharmacological actions of SQ 29,548, a novel selective thromboxane antagonist. J Pharmacol Exp Ther 234: 435-441. (Pubitemid 15241865)
20. Perzborn E, Fiedler VB, Seuter F, Stasch JP, Weber H, et al. (1990) Characterization of Bay U 3405, a novel thromboxane A2/endoperoxide receptor antagonist. Stroke 21: IV143-145.
21. Selg E, Buccellati C, Andersson M, Rovati GE, Ezinga M, et al. (2007) Antagonism of thromboxane receptors by diclofenac and lumiracoxib. Br J Pharmacol 152: 1185-1195. (Pubitemid 350242444)
22. Ford-Hutchinson AW, Girard Y, Lord A, Jones TR, Cirino M, et al. (1989) The pharmacology of L-670,596, a potent and selective thromboxane/prostaglandin endoperoxide receptor antagonist. Can J Physiol Pharmacol 67: 989-993. (Pubitemid 20002349)
23. Pydi SP, Bhullar RP, Chelikani P (2012) Constitutively active mutant gives novel insights into the mechanism of bitter taste receptor activation. J Neurochem 122: 537-544.
24. Chakraborty R, Pydi SP, Gleim S, Bhullar RP, Hwa J, et al. (2013) New insights into structural determinants for prostanoid thromboxane A2 receptor- and prostacyclin receptor-g protein coupling. Mol Cell Biol 33: 184-193.
25. Chidiac P, Hebert TE, Valiquette M, Dennis M, Bouvier M (1994) Inverse agonist activity of beta-adrenergic antagonists. Mol Pharmacol 45: 490-499. (Pubitemid 24094939)
26. Bond RA, Ijzerman AP (2006) Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery. Trends Pharmacol Sci 27: 92-96. (Pubitemid 43184030)
27. Ballesteros JA, Weinstein H (1995) Integrated methods for the construction of three dimensional models and computational probing of structure-function relations in G-protein coupled receptors. Methods in Neuroscience 25: 366-428.
28. Dryja TP, McEvoy JA, McGee TL, Berson EL (2000) Novel rhodopsin mutations Gly114Val and Gln184Pro in dominant retinitis pigmentosa. Invest Ophthalmol Vis Sci 41: 3124-3127.
29. Geller F, Reichwald K, Dempfle A, Illig T, Vollmert C, et al. (2004) Melanocortin-4 receptor gene variant I103 is negatively associated with obesity. Am J Hum Genet 74: 572-581. (Pubitemid 38325928)
30. Shibata K, Hirasawa A, Moriyama N, Kawabe K, Ogawa S, et al. (1996) Alpha 1a-adrenoceptor polymorphism: pharmacological characterization and association with benign prostatic hypertrophy. Br J Pharmacol 118: 1403-1408. (Pubitemid 26248791)
31. Mo XL, Tao YX (2013) Activation of MAPK by inverse agonists in six naturally occurring constitutively active mutant human melanocortin-4 receptors. Biochim Biophys Acta 1832: 1939-1948.
32. Tang WH, Stitham J, Gleim S, Di Febbo C, Porreca E, et al. (2011) Glucose and collagen regulate human platelet activity through aldose reductase induction of thromboxane. J Clin Invest 121: 4462-4476.
33. Blann AD, Nadar SK, Lip GY (2003) The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J 24: 2166-2179. (Pubitemid 37522669)
34. Leytin V, Mody M, Semple JW, Garvey B, Freedman J (2000) Quantification of platelet activation status by analyzing P-selectin expression. Biochem Biophys Res Commun 273: 565-570. (Pubitemid 30599026)
35. Jones RL, Giembycz MA, Woodward DF (2009) Prostanoid receptor antagonists: development strategies and therapeutic applications. Br J Pharmacol 158: 104-145. Canada